Efficacy of Moluodan in Patients With Gastric Intestinal Metaplasia: Analysis of 104 Cases
10.3969/j.issn.1008-7125.2022.12.003
- Author:
Xiaojing ZHU
1
;
Songbo LI
1
;
Jiangyi ZHU
1
;
Jun LIU
1
;
Yongquan SHI
1
;
Jie LIU
2
Author Information
1. Department of Gastroenterology, Xijing Hospital of Air Force Medical University
2. Department of Air Service, Xijing Hospital of Air Force Medical University
- Publication Type:Journal Article
- Keywords:
Chronic Atrophic Gastritis;
Intestinal Metaplasia;
Moluodan;
Stomach Neoplasms
- From:
Chinese Journal of Gastroenterology
2022;27(12):717-722
- CountryChina
- Language:Chinese
-
Abstract:
Background: Gastric mucosal atrophy and intestinal metaplasia (IM) are precancerous conditions of gastric cancer. Although Moluodan has been used in the treatment of chronic atrophic gastritis (CAG), there is little study on efficacy evaluation of Moluodan based on pathological stages. Aims: To assess the efficacy of Moluodan on reversal of gastric mucosal atrophy and IM based on OLGA and OLGIM staging systems, and to analyze the related factors. Methods: A total of 104 patients with CAG and IM from October 2019 to January 2022 at Xijing Hospital of Air Force Medical University were enrolled retrospectively in this study. All the patients received Moluodan treatment (one bag each time, three times daily) for 6 months. Changes of OLGA and OLGIM stages before and after treatment, and the related factors affecting the efficacy were analyzed. Results: After treatment with Moluodan for 6 months, the reversal rates for gastric mucosal atrophy and IM were 47.1% (49/104) and 51.0% (53/104), respectively, and the overall efficacy was 65.4% (68/104). There were 49.3% (34/69) and 52.4% (22/42) of patients with higher OLGA and OLGIM stages (III-) reversed to lower stages (0-Ⅱ), respectively. In addition, patients with OLGA and OLGIM stage III- showed a higher reversal rate than those with stage -Ⅱ (all P<0.01). No correlations were found between the demographic data, life and dietary styles, family history of gastric cancer, operation history, comorbidities, severity of mucosal inflammation and the efficacy of Moluodan (all P>0.05). Conclusions: Moluodan could reverse gastric mucosal atrophy and IM effectively in patients with CAG, which suggests that Moluodan has good potential in prevention of gastric cancer.
